Preview

Атеротромбоз

Расширенный поиск

АПИКСАБАН В ЛЕЧЕНИИ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ

https://doi.org/10.21518/2307-1109-2015-1-52-64

Полный текст:

Аннотация

Сердечно-сосудистые заболевания — наиболее распространенные патологии в России. Они обусловливают более 50% летальных случаев, значительная доля которых ассоциирована с развитием системных тромбоэмболий и инсульта. При этом фибрилляция предсердий значительно увеличивает частоту тромботических событий. Для их профилактики показано применение антикоагулянтов. В последнее время все большее распространение получают новые оральные антикоагулянты (НОАК), применение которых не требует постоянного контроля международного нормализованного отношения. В статье рассмотрена проблема применения одного из НОАК — апиксабана для терапии пациентов на фоне фибрилляции предсердий.

Об авторах

О. О. Шахматова
Институт кардиологии им. А.Л. Мясникова ФГБУ РКНПК МЗ РФ
Россия


Е. П. Панченко
Институт кардиологии им. А.Л. Мясникова ФГБУ РКНПК МЗ РФ
Россия


Список литературы

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991; 22(8): 983–8.

2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patientswith atrial fibrillation. N Engl J Med, 2009; 361(12): 1139–51.

3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvularatrial fibrillation. N Engl J Med, 2011; 365(10): 883–91.

4. Granger C.B., Alexander J.H., McMurray J.J.V. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med, 2011; 365: 981–992.

5. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart

6. Disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease. Thrombosis and haemostasis 2013; 110(6): 1087–107.

7. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circulation Cardiovascular quality and outcomes, 2008; 1(2): 84–91.

8. Gallego P, Roldan V, Marin F, et al. SAME-TTR score, time in therapeutic range and outcomes in anticoagulated patients with atrial fibrillation. Am J Med, 2014.

9. Azoulay L, Dell’Aniello S, Simon TA, et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. EurHeart J, 2014; 35(28): 1881–7.

10. Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMETT2R2scoreto poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation. Chest, 2014.

11. S J. Connolly, JEikelboom, C Joyner, et al. Apixaban in Patients with Atrial Fibrillation. N Engl J Med, 2011; 364: 806–81.

12. L Wallentin L, RD. Lopes RD, M Hanna M et al. Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted INR Control for Stroke Prevention in Atrial Fibrillation. Circulation., 2013; 127: 2166–2176.

13. Easton JD, Lopes RD, Bahit M, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. The Lancet Neurology, Volume 11, Issue 6, 503–511.

14. JH. Alexander, RD. Lopes, L Thomas et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal, (2014), 35: 224–232.

15. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Longterm Anticoagulation Therapy) trial analysis. Circulation, 2014; 129(9): 961–70.

16. Wang X, Tirucherai G, Hlgen A, et al. Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev. 2014; 1: 187. Abstract.

17. Инструкция по применению препарата ELIQUIS (США) http://packageinserts.bms.com/pi/pi_eliquis.pdf

18. Langenberg M, Hellemons BS, van Ree JW, et al. Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice. BMJ, 1996; 313(7071): 1534.

19. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Annals of internal medicine, 2009; 151(5): 297–305.

20. Palareti G, Salomone L, Cavazza M, et al. Stroke/thromboembolism and intracranial hemorrhage in a ‘real world’ atrial fibrillation population: The CAFBO STUDY (Complications of Atrial Fibrillation in the BOlogna area). Chest, 2014.

21. Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med, 1999; 159(7): 677–85.

22. Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a metaanalysis of randomized trials. Journal of the American Geriatrics Society, 2014; 62(5): 857–64.

23. G Flaker, RD. Lopes, SM. Al-Khatib et al. Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation. JACC, 2014, Vol. 63, No. 11, 2014: 1082–7.

24. Инструкция по применению препарата Eliquis, Великобритания. http://www.medicines.org.uk/emc/medicine/27220/SPC/Eliquis+5+mg+film-coated+tablets.

25. Пресс-релиз Bristol-Myers Squibb и Pfizer от 17.07.2014 http://news.bms.com/pressrelease/bristolmyerssquibb-and-pfizer-announce-enrollment-firstpatientphase-iv-emanate-tri.

26. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/. American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation, 2014; 130: e199— e267, doi:10.1161/CIR.0000000000000041.

27. Sardar, Partha et al. Meta-Analysis of Risk of Stroke or Transient Ischemic Attack WithDabigatran for Atrial Fibrillation Ablation. American Journal of Cardiology, Volume 113, Issue 7: 1173—1177.

28. Tomoyuki Nagao, YasuyaInden, Masayuki SHimano et al. Efficacy and Safety of Apixaban in the Patients Undergoing the Ablation of Atrial Fibrillation. PACE, 2015; 38:155–163.

29. https://clinicaltrials.gov/ct2/show/NCT02227550.

30. Task Force M, Lip GY, Windecker S, et al. Management of antithrombotic therapyin atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular

31. This article is protected by copyright. All rights reserved. Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J, 2014. doi:10.1093/eurheartj/ehu298.

32. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet, 2013; 381: 1107–1115.

33. Слайды к докладу MarkCrowther на научной сессии Американского общества сердца 2014 г. «ANNEXA™-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial, Demonstrating Reversal of Apixaban-Induced Anticoagulation in Older Subjects by Andexanet alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors».

34. http://my.americanheart.org/idc/groups/ahamahpublic/@ wcm/@sop/@scon/documents/downloadable/ ucm_469639.pdf.

35. Пресс-релиз компаний Portola, Bristol-Myers Squibb и Pfizer от 17.04.2014. http://news.bms.com/pressrelease/ portola-bristol-myers-squibb-and-pfizerannounce-statistically-significant-results-fir.


Для цитирования:


Шахматова О.О., Панченко Е.П. АПИКСАБАН В ЛЕЧЕНИИ ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ. Атеротромбоз. 2015;(1):52-64. https://doi.org/10.21518/2307-1109-2015-1-52-64

For citation:


Шахматов О.О., Панченко Е.П. . Atherothrombosis Journal. 2015;(1):52-64. (In Russ.) https://doi.org/10.21518/2307-1109-2015-1-52-64

Просмотров: 372


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)